Want to see EYPT full AI Analyst Report?
EYPT Stock Chart & Stats
$14.93
$0.01(0.11%)
At close: 4:00 PM EST
$14.93
$0.01(0.11%)
Day’s Range― - ―
52-Week Range$9.40 - $19.11
Previous CloseN/A
Volume354.62K
Average Volume (3M)1.44M
Market Cap
$1.12B
Enterprise Value$908.30
Total Cash (Recent Filing)$222.54M
Total Debt (Recent Filing)$22.31M
Price to Earnings (P/E)―
Beta2.02
Next Earnings
Aug 05, 2026EPS Estimate
-0.95Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.50
Shares Outstanding83,841,300
10 Day Avg. Volume1,532,265
30 Day Avg. Volume1,436,754
Financial Highlights & Ratios
PEG Ratio-0.16
Price to Book (P/B)4.37
Price to Sales (P/S)42.66
P/FCF Ratio-5.50
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$41.60Price Target Upside178.63% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-3.56
Revenue Forecast (FY)$1.76M
Bulls Say, Bears Say
Bulls Say
Clinical Momentum & Differentiated MOAEyePoint's DURAVYU program combines robust Phase II efficacy across >190 patients with a differentiated multi-mechanism MOA and imminent pivotal Phase III readouts (LUGANO mid‑2026, LUCIA shortly after). These durable clinical assets underpin product differentiation and sustained market opportunity if trials succeed, providing a structural path to commercial scale beyond short-term fluctuations.
Manufacturing And Commercial ReadinessHaving an on-line cGMP Northbridge facility plus expanded commercial and regulatory leadership materially reduces execution risk for CMC/NDA and launch activities. Ambient-temperature storage and standard intravitreal administration simplify logistics and support faster commercialization and consistent supply, improving long-term go-to-market feasibility.
High Gross Margins And Low LeverageEyePoint's product economics show very high gross margins, indicating attractive unit profitability when scale is achieved, while low leverage (debt/equity ~0.09) preserves balance-sheet flexibility. Together these structural advantages reduce refinancing pressure and support investment in trials and commercialization without heavy interest burdens.
Bears Say
Heavy Cash BurnOperating cash flow and free cash flow have been deeply negative on a TTM basis, implying that reported losses translate into real cash outflows. Sustained burn at this scale elevates financing risk, potentially forcing dilutive equity raises or partnerships that could alter strategic control and long-term economics if trial timelines slip.
Sharp Revenue Decline And Widening LossesA severe revenue collapse and materially wider net losses show the company lacks near-term commercial scale, leaving fixed R&D and manufacturing costs misaligned with current sales. This structural mismatch erodes equity and increases dependency on external funding until pivotal approvals deliver meaningful revenue.
Regulatory Settlement And Ongoing Compliance ObligationsThe DOJ settlement and five‑year Corporate Integrity Agreement impose prolonged compliance, oversight, and reporting burdens that raise operating costs and limit flexibility in federal markets. Noncompliance risks penalties or exclusion from Medicare/Medicaid, creating a durable regulatory constraint on commercial execution in core channels.
EyePoint Pharmaceuticals News
EYPT FAQ
What was Eyepoint Pharma’s price range in the past 12 months?
Eyepoint Pharma lowest stock price was $9.40 and its highest was $19.11 in the past 12 months.
What is Eyepoint Pharma’s market cap?
Eyepoint Pharma’s market cap is $1.12B.
When is Eyepoint Pharma’s upcoming earnings report date?
Eyepoint Pharma’s upcoming earnings report date is Aug 05, 2026 which is in 15 days.
How were Eyepoint Pharma’s earnings last quarter?
Eyepoint Pharma released its earnings results on May 06, 2026. The company reported -$0.99 earnings per share for the quarter, missing the consensus estimate of -$0.805 by -$0.185.
Is Eyepoint Pharma overvalued?
According to Wall Street analysts Eyepoint Pharma’s price is currently Undervalued.
Does Eyepoint Pharma pay dividends?
Eyepoint Pharma does not currently pay dividends.
What is Eyepoint Pharma’s EPS estimate?
Eyepoint Pharma’s EPS estimate is -0.95.
How many shares outstanding does Eyepoint Pharma have?
Eyepoint Pharma has 83,841,300 shares outstanding.
What happened to Eyepoint Pharma’s price movement after its last earnings report?
Eyepoint Pharma reported an EPS of -$0.99 in its last earnings report, missing expectations of -$0.805. Following the earnings report the stock price went down -2.909%.
Which hedge fund is a major shareholder of Eyepoint Pharma?
Currently, no hedge funds are holding shares in EYPT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
EyePoint Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$41.60 (178.63% Upside)
$41.60 (178.63% Upside)
Blogger Sentiment
Bullish
EYPT Sentiment 70%
Sector Average 66%
Sector Average 66%
Insider Transactions
Sold Shares
Worth $109.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.2%
Last 30 Days ▲ 12.1%
Last 30 Days ▲ 12.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
29.12%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-20.51%
Trailing 12-Months
Company Description
Eyepoint Pharma
EyePoint Pharmaceuticals, Inc. is a pharmaceutical firm dedicated to the creation and marketing of ophthalmic solutions for various eye ailments. Its operations span the United States, China, and the United Kingdom. Among its commercialized product portfolio are ILUVIEN, an injectable, sustained-release micro-insert designed to treat diabetic macular edema, and YUTIQ, an intravitreal implant containing fluocinolone acetonide, which targets chronic non-infectious uveitis impacting the posterior segment of the eye. The company also offers DEXYCU, a dexamethasone intraocular suspension, utilized to manage post-operative ocular inflammation, such as that occurring after cataract surgery. Looking ahead, EyePoint is actively developing several pipeline therapies. This includes EYP-1901, a novel, bioerodible tyrosine kinase inhibitor currently formulated for twice-yearly administration, which is under development for conditions like wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion. Additionally, YUTIQ50 is being advanced as a treatment for chronic non-infectious uveitis affecting the posterior region of the eye. To bolster its market reach and development efforts, the company maintains strategic alliances with entities such as Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. Furthermore, a commercial collaboration with ImprimisRx PA, Inc. specifically focuses on the joint promotion of DEXYCU for inflammation following ocular surgery. Incorporated in 1987, the organization was previously known as pSivida Corp. before officially rebranding as EyePoint Pharmaceuticals, Inc. in March 2018. Its corporate headquarters are situated in Watertown, Massachusetts.
EYPT Stock 12 Month Forecast
Average Price Target
$41.60
▲(178.63% Upside)
Technical Analysis
Urogen Pharma
―
Meiragtx Holdings
―
Stoke Therapeutics
―
Tango Therapeutics
―
Pharming Group
―
Ownership Overview
10.72% Insiders
19.61% Mutual Funds
0.54% Other Institutional Investors
56.72% Public Companies and
Individual Investors